Imagine a single treatment that keeps your worst cholesterol numbers down for a whole year.
No daily pills. No monthly shots. Just done.
For the Black community especially, which sees much higher rates of heart disease, a groundbreaking new gene-editing trial is turning out to be a big deal.
A full year after a single treatment, participants are still seeing significantly lower LDL cholesterol.
This is more than just some cool science.
It is a potential lifeline for closing a devastating health disparity that has long plagued communities of color.
And it could revolutionize the way we approach heart health and empower individuals to take control of their wellness without the burden of daily medication.
Here’s what’s going on.
Last Friday, scientists announced exciting news about the potential to treat common diseases by changing people’s genetic traits that are risk factors for them.
According to The New York Times, the small, recent study, involving 15 patients, revealed that those receiving the highest dose of a genetic modification to treat high cholesterol saw their levels plummet by half with those numbers sticking around for a full year.
The breakthrough was shared at the European Society of Cardiology Congress and later published in the New England Journal of Medicine. Earlier this year, another clinical trial using a different single-use gene editing technique reported significant reductions in “bad” LDL cholesterol among 35 patients as well.
The researchers point out that although both studies are important steps in safety testing, we are still at the beginning of this process. It could take a few years before these new methods are used in doctors’ offices.
However, they note that the shift in perspective is clear: what used to seem like an unrealistic idea is now becoming more achievable because they now have more proof that these methods are effective and provide long-lasting results.
“As a preventive cardiologist, you’re really thinking, I’ll treat people chronically for many, many years,” Dr. Luke Laffin, a cardiologist at the Cleveland Clinic who led the new study, told The Times. “To have the possibility of giving a one-time cure is much more akin to other specialties, like a surgeon.”
The quest for a single, effective treatment for heart disease is highly appealing to patients and doctors alike, especially given the staggering statistics that it is the No. 1 cause of death in Americans. Despite a growing array of medications, injection and lifestyle modifications aimed at reducing heart disease risk, it’s often tough for people to remain consistent in these efforts. Roughly half of the individuals who start a daily statin eventually discontinue it and many who could benefit from such medications never even begin treatment. This situation often stems from a variety of barriers, including limited access to healthcare, difficulties in managing complex medication routines and the daunting prospect of a lifelong dependence on drugs. But recent advancements in gene therapy offer a glimmer of hope.
In the new study (funded by CRISPR Therapeutics), patients received a one-time infusion of lipid nanoparticles – tiny fat bubbles designed to deliver gene-editing tools directly to the liver. These tools target and disable the ANGPTL3 gene, which plays a critical role in cholesterol metabolism.
The experiment was partly inspired by the discovery of individuals with a non-working version of the ANGPTL3 gene. These people tend to have very low cholesterol and triglyceride levels, which lowers their chances of heart disease. Using gene-editing technology, scientists are attempting to replicate this beneficial trait.
According to ScienceDirect, these naturally occurring versions of the ANGPTL3 gene are most widely documented and studied in populations of European descent. However, these important variants are, notably, naturally present in people of African ancestry.
Samarth Kulkarni, CEO of CRISPR Therapeutics, said the results from the next part of the trial, involving another small group of patients, are expected by the end of the year. After that, they will begin talks with regulators about a large Phase 3 trial to test how safe and effective the treatment is. Since gene-editing is a new technology with many uncertainties regarding safety and long-term effects, regulators require that patients be monitored for 15 years.
Dr. Kiran Musunuru, a cardiologist at the University of Pennsylvania, who supports the study but wasn’t part of it, warns that we are still in the beginning stages. He believes that larger studies are necessary and thinks this could be a treatment option for patients by the early 2030s.
Imagine a world where a genetic predisposition to heart disease is no longer a life sentence. Sure, we’re not there yet, but gene-altering therapy has officially shifted this reality from sci-fi to standard medicine.
By fixing the root cause of bad cholesterol with a single, targeted approach, we are looking at a future with fewer daily pills, less anxiety and millions of healthier hearts.
This may be more than just a medical breakthrough. It could be a total rewrite of public health.
